Search

Search Results

• The efficacy of apremilast in pemphigus: a systematic review of case reports

  Roudin H. Alhasawi, Esraa A. Shaheen, Noura M. Alshabanat, Reem Brashi, Walaa Abdu Ahmed, Shumukh H. Alqahtani, Ethar G. Alharbi, Mazin Aljabri

  07-05-2025

  https://doi.org/10.4081/dr.2025.10245

  870

  PDF: 387

  SUPPLEMENTARY MATERIAL: 26

  HTML: 7
• 

  Erythrodermic psoriasis treated with apremilast

  John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

  19-09-2016

  https://doi.org/10.4081/dr.2016.6599

  2110

  PDF: 955

  HTML: 600
• 

  Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

  Alexandra Maria Giovanna Brunasso, Sanja Javor, Emanuele Pontali, Simona Sola, Cesare Massone

  29-07-2021

  https://doi.org/10.4081/dr.2021.8797

  3049

  PDF: 638

  HTML: 10
• 

  Atopic dermatitis: a brief review of recent advances in its management

  Sultan Daghafak Alenazi

  23-05-2023

  https://doi.org/10.4081/dr.2023.9678

  2372

  PDF: 1396

  HTML: 104
• 

  Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

  25-06-2020

  https://doi.org/10.4081/dr.2020.8642

  1340

  PDF: 743

  HTML: 6
• 

  Certolizumab to treat hidradenitis suppurativa

  Asem Shadid, Saud Alobaida, Yousef Binamer

  27-10-2022

  https://doi.org/10.4081/dr.2022.9566

  1929

  PDF: 714

  HTML: 28
• 

  Maculopapular sarcoidosis: the importance of skin signs

  Giovanna Galdo, Gelsomina Luongo, Daniela Capacchione, Damiano Abeni, Marta Grimaldi, Luca Fania

  16-09-2022

  https://doi.org/10.4081/dr.2022.9561

  980

  PDF: 370

  HTML: 24
• 

  Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

  Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9091

  2617

  PDF: 623

  HTML: 6

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1720

  PDF: 656

  HTML: 94
• 

  Measuring the impact of pruritus in patients with epidermolysis bullosa: evaluation with an itch-specific instrument

  Ashjan Alheggi, Raneem Alnutaifi, Manal Alkhonezan, Norah Almudawi, Renad Alsuhaibani, Philip Moons, Turki Aljuhani

  18-05-2023

  https://doi.org/10.4081/dr.2023.9700

  1159

  PDF: 359

  APPENDIX S1: 169

  HTML: 7

• S-MAPA: bridging the gap in psoriasis severity assessment

  Trang Thi Thuy Vu, Chuyen Thi Hong Nguyen, Trung The Van

  28-05-2025

  https://doi.org/10.4081/dr.2025.10231

  601

  PDF: 266

  HTML: 13
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1158

  PDF: 813

  HTML: 41